Sun Pharma.Inds.
Drug Manufacturers - Specialty & Generic · SUNPHARMA
Mega CapHealthcareMature Stable
Dilip Shanghvi
Managing Director · Visionary
Company DNA
Founder-Centric
About
Sun Pharma.Inds. is a Mega Cap company in the Healthcare sector, listed on NSE as SUNPHARMA. With a market cap of ₹434K Cr and revenue of ₹52K Cr, it is currently in the Mature Stable phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Strongly influenced by the vision and methodical, quiet management style of founder Dilip Shanghvi, driving strategic growth. Its strategic mandate: To sustain leadership, the focus must shift from volume generics to complex specialty R&D and high-margin product pipelines.
FAQ
What kind of company is Sun Pharma.Inds.?
Sun Pharma.Inds. is a Mega Cap Healthcare company (SUNPHARMA) in the Mature Stable phase with a market cap of ₹434K Cr. It is classified as Founder-Centric in culture.
What is Sun Pharma.Inds.'s culture and work environment like?
Sun Pharma.Inds. has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Strongly influenced by the vision and methodical, quiet management style of founder Dilip Shanghvi, driving strategic growth.
Who leads Sun Pharma.Inds.?
Sun Pharma.Inds. is led by Dilip Shanghvi (Managing Director), a Visionary leader with 48 years of experience.
What are Sun Pharma.Inds.'s financials?
Sun Pharma.Inds. reported revenue of ₹52K Cr in FY25 with a 5-year revenue CAGR of 10.6%. Operating margin: 24.2%. Market cap: ₹434K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleMature Stable
Strongly influenced by the vision and methodical, quiet management style of founder Dilip Shanghvi, driving strategic growth.
Mandate
To sustain leadership, the focus must shift from volume generics to complex specialty R&D and high-margin product pipelines.
To sustain leadership, the focus must shift from volume generics to complex specialty R&D and high-margin product pipelines.
Financials
Revenue FY25₹52K Cr
PAT FY25₹11K Cr
Rev CAGR 5Y10.6%
OPM24.2%
NPM21%
ROE15.1%
ROCE17%
P/E39.5
Fwd P/E31.7
P/B5.6
D/E6.7
Mkt Cap₹434K Cr
Promoter55.6%
Institutional28.7%
Similar Culture
Could You Lead Sun Pharma.Inds.?
Take the Genome Benchmark →